← Evidence map

ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2015

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.

Vera HirshPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

36 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 26123538